Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:SRRK NASDAQ:TLX NASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$27.73+2.1%$19.00$9.57▼$29.34$3.83B12.03 million shs2.39 million shsSRRKScholar Rock$31.58$35.39$6.76▼$46.98$3.04B0.361.30 million shs1.26 million shsTLXTelix Pharmaceuticals$9.29+2.7%$13.08$8.93▼$30.36$3.14BN/A62,324 shs206,536 shsTNFATNF Pharmaceuticals$3.59-4.8%$9.77$3.24▼$195.00$6.41M2.04232,719 shs392,430 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-6.57%+23.33%+65.47%+60.11%+22.28%SRRKScholar Rock+0.54%-3.28%-1.16%-8.25%+293.28%TLXTelix Pharmaceuticals-0.11%-5.24%-20.19%-47.60%+904,999,900.00%TNFATNF Pharmaceuticals+14.24%-21.95%-61.05%-78.59%+376,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$27.73+2.1%$19.00$9.57▼$29.34$3.83B12.03 million shs2.39 million shsSRRKScholar Rock$31.58$35.39$6.76▼$46.98$3.04B0.361.30 million shs1.26 million shsTLXTelix Pharmaceuticals$9.29+2.7%$13.08$8.93▼$30.36$3.14BN/A62,324 shs206,536 shsTNFATNF Pharmaceuticals$3.59-4.8%$9.77$3.24▼$195.00$6.41M2.04232,719 shs392,430 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-6.57%+23.33%+65.47%+60.11%+22.28%SRRKScholar Rock+0.54%-3.28%-1.16%-8.25%+293.28%TLXTelix Pharmaceuticals-0.11%-5.24%-20.19%-47.60%+904,999,900.00%TNFATNF Pharmaceuticals+14.24%-21.95%-61.05%-78.59%+376,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1455.58% UpsideSRRKScholar Rock 3.20Buy$45.7544.87% UpsideTLXTelix Pharmaceuticals 2.80Moderate Buy$22.33140.40% UpsideTNFATNF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TNFA, ARWR, SRRK, and TLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.008/28/2025TLXTelix PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral8/28/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/21/2025SRRKScholar RockJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/7/2025SRRKScholar RockBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $45.007/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$53.007/28/2025ARWRArrowhead PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025SRRKScholar RockCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,079.99N/AN/A$1.54 per share18.01SRRKScholar Rock$33.19M91.47N/AN/A$3.94 per share8.02TLXTelix Pharmaceuticals$516.72M6.08$0.12 per share79.34$1.12 per share8.29TNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0019.35N/AN/AN/AN/AN/ATNFATNF Pharmaceuticals-$23.36M-$231.00N/A∞N/AN/A-69.21%-33.98%11/12/2025 (Estimated)Latest TNFA, ARWR, SRRK, and TLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025TNFATNF PharmaceuticalsN/A-$18.00N/A-$0.18N/AN/A8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87SRRKScholar Rock0.216.336.33TLXTelix Pharmaceuticals0.992.782.66TNFATNF PharmaceuticalsN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%SRRKScholar Rock91.08%TLXTelix PharmaceuticalsN/ATNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%SRRKScholar Rock13.30%TLXTelix PharmaceuticalsN/ATNFATNF Pharmaceuticals0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/ATNFATNF Pharmaceuticals61.79 million1.78 millionN/ATNFA, ARWR, SRRK, and TLX HeadlinesRecent News About These CompaniesTNF Pharmaceuticals (NASDAQ:TNFA) Stock Rating Upgraded by Wall Street ZenSeptember 7 at 2:17 AM | americanbankingnews.comTNF Pharmaceuticals (NASDAQ:TNFA) Sees Large Volume Increase - What's Next?September 5, 2025 | marketbeat.comTNF Pharmaceuticals (NASDAQ:TNFA) Hits New 12-Month Low - Should You Sell?September 4, 2025 | marketbeat.comTNF Pharmaceuticals Announces Closing of $7 Million Private PlacementSeptember 4, 2025 | businesswire.comTNF Pharmaceuticals stock climbs after securing exclusive crypto computing rightsSeptember 2, 2025 | investing.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comTNF Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, September 2nd (NASDAQ:TNFA)August 29, 2025 | americanbankingnews.comTNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing ComplianceAugust 29, 2025 | finance.yahoo.comTNF Pharmaceuticals announces improved financial positionAugust 20, 2025 | msn.comTNF Pharmaceuticals Strengthens Financial Position for Growth and Value CreationAugust 19, 2025 | businesswire.comTNF Pharmaceuticals Inc Ordinary Shares TNFA - MorningstarJuly 11, 2025 | morningstar.comMAkers files written objection to her Judicial Investigative admonishmentJuly 4, 2025 | wvgazettemail.comWDorothy Marillyn AkersJuly 2, 2025 | chattanoogan.comCNewly-signed running back Cam Akers has already changed his jersey numberJune 30, 2025 | msn.comTNF Pharmaceuticals, Inc. (TNFA) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAdmonishing Akers, Sweeney Wrong; Will Make Matters WorseJune 26, 2025 | wvmetronews.comWTNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory DiseaseJune 25, 2025 | finance.yahoo.comClinton native Cam Akers signs with New Orleans SaintsJune 17, 2025 | msn.comSaints' Cam Akers: Gets chance with SaintsJune 15, 2025 | cbssports.comFormer Houston Texans RB Cam Akers signs one-year deal with the SaintsJune 14, 2025 | msn.comCam Akers, Saints Reportedly Agree to Contract in Free Agency, Updated Depth ChartJune 14, 2025 | bleacherreport.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, ARWR, SRRK, and TLX Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$27.73 +0.56 (+2.06%) Closing price 04:00 PM EasternExtended Trading$27.84 +0.11 (+0.38%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Scholar Rock NASDAQ:SRRK$31.58 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$31.84 +0.27 (+0.84%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Telix Pharmaceuticals NASDAQ:TLX$9.29 +0.24 (+2.65%) Closing price 04:00 PM EasternExtended Trading$9.27 -0.02 (-0.22%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.TNF Pharmaceuticals NASDAQ:TNFA$3.59 -0.18 (-4.77%) Closing price 04:00 PM EasternExtended Trading$3.67 +0.08 (+2.23%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
